Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning

Significance Gaucher disease is a rare genetic disorder that has crippling health consequences. Mutations in the GBA1 gene are known to disrupt the enzyme glucocerebrosidase-1, but it is not known, at atom-level detail, as to how enzyme function is lost. This study uses multiscale simulations and deep learning to define precisely the mechanism underlying the disruption of glucocerebrosidase-1 and, in particular, its interaction with the facilitator protein, saposin C. The lysosomal enzyme glucocerebrosidase-1 (GCase) catalyzes the cleavage of a major glycolipid glucosylceramide into glucose and ceramide. The absence of fully functional GCase leads to the accumulation of its lipid substrates in lysosomes, causing Gaucher disease, an autosomal recessive disorder that displays profound genotype–phenotype nonconcordance. More than 250 disease-causing mutations in GBA1, the gene encoding GCase, have been discovered, although only one of these, N370S, causes 70% of disease. Here, we have used a knowledge-based docking protocol that considers experimental data of protein–protein binding to generate a complex between GCase and its known facilitator protein saposin C (SAPC). Multiscale molecular-dynamics simulations were used to study lipid self-assembly, membrane insertion, and the dynamics of the interactions between different components of the complex. Deep learning was applied to propose a model that explains the mechanism of GCase activation, which requires SAPC. Notably, we find that conformational changes in the loops at the entrance of the substrate-binding site are stabilized by direct interactions with SAPC and that the loss of such interactions induced by N370S and another common mutation, L444P, result in destabilization of the complex and reduced GCase activation. Our findings provide an atomistic-level explanation for GCase activation and the precise mechanism through which N370S and L444P cause Gaucher disease.

[1]  N. Radin,et al.  Mechanism of activation of glucocerebrosidase by co-beta-glucosidase (glucosidase activator protein). , 1981, Biochimica et biophysica acta.

[2]  Marc N. Offman,et al.  Comparison of a molecular dynamics model with the X-ray structure of the N370S acid-beta-glucosidase mutant that causes Gaucher disease. , 2011, Protein engineering, design & selection : PEDS.

[3]  Alexandre M. J. J. Bonvin,et al.  CPORT: A Consensus Interface Predictor and Its Performance in Prediction-Driven Docking with HADDOCK , 2011, PloS one.

[4]  A. Tylki-Szymańska,et al.  Gaucher disease due to saposin C deficiency, previously described as non-neuronopathic form--no positive effects after 2-years of miglustat therapy. , 2011, Molecular genetics and metabolism.

[5]  Gregory A Petsko,et al.  Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. , 2006, Nature chemical biology.

[6]  F. Felicetti,et al.  The N370S (Asn370-->Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin C. , 2005, The Biochemical journal.

[7]  D. Jain,et al.  Gaucher disease gene GBA functions in immune regulation , 2012, Proceedings of the National Academy of Sciences.

[8]  M. Horowitz,et al.  Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. , 2011, Blood Cells, Molecules & Diseases.

[9]  K. Sandhoff,et al.  Lysosomal degradation of membrane lipids , 2010, FEBS letters.

[10]  R. Schultz-Heienbrok,et al.  Crystal structures of human saposins C andD: implications for lipid recognition and membrane interactions. , 2008, Structure.

[11]  W. Qin,et al.  Functional Organization of Saposin C , 1996, The Journal of Biological Chemistry.

[12]  Jeffrey D. Evanseck,et al.  Chapter 13 Principal Components Analysis: A Review of its Application on Molecular Dynamics Data , 2006 .

[13]  D. Ritchie,et al.  Evaluation of Protein Docking Predictions Using Hex 3.1 in CAPRI Rounds 1{2 , 2002 .

[14]  D. Tieleman,et al.  The MARTINI force field: coarse grained model for biomolecular simulations. , 2007, The journal of physical chemistry. B.

[15]  R. L. Lieberman,et al.  A Guided Tour of the Structural Biology of Gaucher Disease: Acid-β-Glucosidase and Saposin C , 2011, Enzyme research.

[16]  David W Ritchie,et al.  Recent progress and future directions in protein-protein docking. , 2008, Current protein & peptide science.

[17]  Oliver Beckstein,et al.  MDAnalysis: A toolkit for the analysis of molecular dynamics simulations , 2011, J. Comput. Chem..

[18]  Marc N. Offman,et al.  Molecular Basis of Reduced Glucosylceramidase Activity in the Most Common Gaucher Disease Mutant, N370S , 2010, The Journal of Biological Chemistry.

[19]  R. Brady,et al.  Prevalence of nine mutations among Jewish and non-Jewish Gaucher disease patients. , 1993, American journal of human genetics.

[20]  P. Kaplan,et al.  The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. , 2000, Archives of internal medicine.

[21]  Carl Doersch,et al.  Tutorial on Variational Autoencoders , 2016, ArXiv.

[22]  K. Xia,et al.  Glucocerebrosidase Gene L444P mutation is a risk factor for Parkinson's disease in Chinese population , 2010, Movement disorders : official journal of the Movement Disorder Society.

[23]  Li Han,et al.  Evaluation of Dimensionality-reduction Methods from Peptide Folding-unfolding Simulations. , 2013, Journal of chemical theory and computation.

[24]  G. Privé,et al.  Crystal structures of saposins A and C , 2006, Protein science : a publication of the Protein Society.

[25]  G. Rennert,et al.  The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients , 2009, American journal of hematology.

[26]  D. Ritchie,et al.  Protein docking using spherical polar Fourier correlations , 2000, Proteins.

[27]  S. Weiler,et al.  Identification of the binding and activating sites of the sphingolipid activator protein, saposin C, with glucocerebrosidase , 1995, Protein science : a publication of the Protein Society.

[28]  Seon-Yong Jeong,et al.  Clinical and genetic characteristics of Korean patients with Gaucher disease. , 2011, Blood cells, molecules & diseases.

[29]  C. Schütte,et al.  Supplementary Information for “ Constructing the Equilibrium Ensemble of Folding Pathways from Short Off-Equilibrium Simulations ” , 2009 .

[30]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[31]  D. Kern,et al.  Dynamic personalities of proteins , 2007, Nature.

[32]  Shang Gao,et al.  Deep clustering of protein folding simulations , 2018 .

[33]  A. Vasella,et al.  Glycosidase mechanisms. , 2002, Current opinion in chemical biology.

[34]  J. K. Park,et al.  Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. , 2000, American journal of human genetics.

[35]  The studies on substrate, product and inhibitor binding to a wild-type and neuronopathic form of human acid-β-glucosidase , 2007, Journal of molecular modeling.

[36]  Shang Gao,et al.  Deep clustering of protein folding simulations , 2018, BMC Bioinformatics.

[37]  G. Grabowski,et al.  Human acid beta-glucosidase. Use of inhibitory and activating monoclonal antibodies to investigate the enzyme's catalytic mechanism and saposin A and C binding sites. , 1991, The Journal of biological chemistry.

[38]  R. Tamargo,et al.  The role of saposin C in Gaucher disease. , 2012, Molecular genetics and metabolism.

[39]  W. V. Gunsteren,et al.  Validation of the 53A6 GROMOS force field , 2005, European Biophysics Journal.

[40]  P. Gómez-Puertas,et al.  An evolutionary and structure‐based docking model for glucocerebrosidase–saposin C and glucocerebrosidase–substrate interactions—Relevance for Gaucher disease , 2008, Proteins.

[41]  Gianni De Fabritiis,et al.  Dimensionality reduction methods for molecular simulations , 2017, ArXiv.

[42]  Thomas Kolter,et al.  Principles of lysosomal membrane degradation: Cellular topology and biochemistry of lysosomal lipid degradation. , 2009, Biochimica et biophysica acta.

[43]  J. Sussman,et al.  X‐ray structure of human acid‐β‐glucosidase, the defective enzyme in Gaucher disease , 2003, EMBO reports.

[44]  E. Sidransky Gaucher disease: insights from a rare Mendelian disorder. , 2012, Discovery medicine.

[45]  Hongyu Zhao,et al.  Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage , 2010, Proceedings of the National Academy of Sciences.

[46]  Y. Eto,et al.  Clinical and Molecular Characteristics of Japanese Gaucher Disease , 1999, Neurochemical Research.

[47]  G. Grabowski Phenotype, diagnosis, and treatment of Gaucher's disease , 2008, The Lancet.

[48]  A. Bonvin,et al.  The HADDOCK web server for data-driven biomolecular docking , 2010, Nature Protocols.

[49]  E. Sidransky,et al.  Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA) , 2008, Human mutation.

[50]  Ying Sun,et al.  Saposin C Is Required for Normal Resistance of Acid β-Glucosidase to Proteolytic Degradation* , 2003, Journal of Biological Chemistry.

[51]  E. Sidransky,et al.  Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease , 2000, Human mutation.